Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eterna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ERNA
Nasdaq
8731
https://eternatx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eterna Therapeutics Inc
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
- May 10th, 2024 12:00 pm
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
- May 8th, 2024 1:31 pm
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus
- May 7th, 2024 12:00 pm
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
- Feb 20th, 2024 1:30 pm
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
- Jan 3rd, 2024 9:15 pm
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO
- Dec 21st, 2023 4:18 pm
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
- Dec 20th, 2023 9:15 pm
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
- Dec 14th, 2023 11:56 pm
Eterna Therapeutics Appoints Dr. James Bristol to Board of Directors
- Nov 2nd, 2023 3:48 pm
Eterna Therapeutics Appoints James Bristol, Ph.D., Pharmaceutical Research and Drug Discovery Veteran, to Board of Directors
- Nov 1st, 2023 12:30 pm
Insider Stock Buying Reaches US$2.7m On Eterna Therapeutics
- Sep 8th, 2023 7:45 pm
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
- Sep 6th, 2023 5:01 pm
EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics
- Sep 6th, 2023 1:40 pm
Eterna Therapeutics Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Lineage Cell Therapeutics
- Sep 6th, 2023 12:00 pm
Eterna Therapeutics Appoints Dorothy Clarke to Board of Directors
- Sep 5th, 2023 3:24 pm
Eterna Therapeutics Appoints Biopharma Industry Veteran Dorothy Clarke to Board of Directors
- Sep 5th, 2023 12:30 pm
Eterna Therapeutics Announces $8.7M Private Placement Transaction
- Jul 18th, 2023 6:24 pm
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
- Jul 18th, 2023 12:00 pm
Eterna Therapeutics Appoints Industry Veterans Binder, Wagner to Board of Directors
- Jul 11th, 2023 3:21 pm
Eterna Therapeutics Appoints Biotech Industry Veterans Brant Binder and Richard Wagner, Ph.D. to Board of Directors
- Jul 11th, 2023 12:30 pm
Scroll